Kadimastem calls for a special general meeting of shareholders to approve the merger with nls

Kadimastem approaches final steps for securing merger completion zurich and ness ziona, israel , jan. 16, 2025 /prnewswire/ -- nls pharmaceutics ltd. ("nls") (nasdaq: nlsp), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and kadimastem ltd.
GM Ratings Summary
GM Quant Ranking